Bionano Genomics (BNGO) vs Femasys (FEMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bionano Genomics (BNGO) has outperformed Femasys (FEMY) over the past year, losing 32.6% versus a loss of 84.6%. Over five years, FEMY leads with a -98.6% price change compared with -100.0% for BNGO. Bionano Genomics is the larger company by market cap ($16.9 million vs $16.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNGO | FEMY |
|---|---|---|
| Share price | $1.44 | $2.00 |
| Market cap | $16.90M | $16.75M |
| 1-day change | -1.71% | -2.20% |
| YTD return | -6.21% | -82.64% |
| 1-year return | -32.63% | -84.59% |
| 5-year return | -99.95% | -98.57% |
| EPS (TTM) | $-3.02 | $-3.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.23 | $22.20 |
| 52-week low | $1.00 | $1.94 |
| Distance from 52-week high | -35.65% | -90.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +248.43% | +616.50% |
| Average volume | 921.59K | 733.12K |
| Shares outstanding | 11.78M | 8.38M |
| Employees | 95 | 51 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNGO has outperformed FEMY by 52.0 percentage points over the past year.
- The two companies sit in different sectors: Bionano Genomics in Industrials and Femasys in Health Care.
About Bionano Genomics
BNGO stock →Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Industrials · Biotechnology: Laboratory Analytical Instruments · 95 employees
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Health Care · Medical/Dental Instruments · 51 employees
BNGO vs FEMY FAQ
Which is bigger, Bionano Genomics or Femasys?
Bionano Genomics (BNGO) is larger, with a market capitalization of $16.90M compared with $16.75M for Femasys (FEMY).
Which stock has performed better over the past year, BNGO or FEMY?
BNGO returned -32.63% over the past 12 months, compared with -84.59% for FEMY (price return, excluding dividends). Past performance does not predict future results.
Are Bionano Genomics and Femasys in the same industry?
No. Bionano Genomics is in the Industrials sector, while Femasys is in Health Care.